RxDoctor Payments Data

Kent Rynders, MD

Family Medicine · Mt Pleasant, IANPI 1225117088

Payments from drug & device makers

$230in general payments, 2019–2025

Across 7 payments — averaging $32.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$132
  • Dexcom, Inc.$47
  • Novo Nordisk$35
  • Lilly USA, LLC$17

What the payments were for

  • Food & beverage$230100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer2$132
Dexcom, Inc.2$47
Novo Nordisk2$35
Lilly USA, LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$230 in reported general payments places this provider in the 60th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$446,763
Medicare patients
681
Services billed
6,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin84$98,641
EliquisApixaban104$76,155
OzempicSemaglutide47$54,213
MounjaroTirzepatide41$46,783
RybelsusSemaglutide21$20,630
XareltoRivaroxaban20$19,634
JanuviaSitagliptin Phosphate16$12,972
Tresiba Flextouch U-100Insulin Degludec15$5,357
Breo ElliptaFluticasone/Vilanterol14$4,598
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$4,421
Memantine Hcl27$3,951
Metoprolol Succinate230$3,844
Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol18$3,823
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$3,361
Dabigatran EtexilateDabigatran Etexilate Mesylate11$3,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$132$76,155104 claims
Novo NordiskOzempic, Rybelsus$35$74,84368 claims
Lilly USA, LLCMounjaro$17$46,78341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Mt Pleasant

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →